Notable Upgrades: Akamai Technologies (AKAM), Vertex Pharmaceuticals (VRTX), Avago Technologies (AVGO) , Threshold Pharmaceuticals (THLD), Intellipharmaceutics (IPCI)

UBS AG is out with a report this morning initiating coverage of Akamai Technologies, Inc. (AKAM) with a ‘Buy’ rating and $70 price target, implying 16% expected return. The Swiss global financial services firm said it sees the cloud services provider as the “Google of internet infrastructure.” Akamai Technologies shares are currently priced at 37.30x […] View the full post at: Notable Upgrades: Akamai Technologies (AKAM), Vertex Pharmaceuticals (VRTX), Avago Technologies (AVGO) , Threshold Pharmaceuticals (THLD), Intellipharmaceutics (IPCI) Related posts: Pre-Market Earnings (May 3) S&P Equity Research Boosts Operating Profit Target For Chevron